(NASDAQ: BLTE) Belite Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.28%.
Belite Bio's earnings in 2026 is -$77,611,000.On average, 10 Wall Street analysts forecast BLTE's earnings for 2026 to be -$109,345,419, with the lowest BLTE earnings forecast at -$162,694,339, and the highest BLTE earnings forecast at -$70,634,898. On average, 8 Wall Street analysts forecast BLTE's earnings for 2027 to be -$93,629,105, with the lowest BLTE earnings forecast at -$183,898,577, and the highest BLTE earnings forecast at -$3,304,557.
In 2028, BLTE is forecast to generate $157,163,140 in earnings, with the lowest earnings forecast at $94,069,712 and the highest earnings forecast at $235,862,730.